News
FSNUY
13.67
-0.73%
-0.10
Weekly Report: what happened at FSNUY last week (0810-0814)?
Weekly Report · 5d ago
DZ BANK AG Reaffirms Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/15 05:06
UBS Sticks to Its Buy Rating for Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/12 08:45
DZ BANK AG Remains a Buy on Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/11 06:15
Fresenius SE price target raised to EUR 52 from EUR 49 at Morgan Stanley
TipRanks · 08/10 18:55
Fresenius SE & Co. KGaA (0OO9) Gets a Buy from Morgan Stanley
TipRanks · 08/10 16:35
Weekly Report: what happened at FSNUY last week (0803-0807)?
Weekly Report · 08/10 10:22
Fresenius SE price target lowered to EUR 55.20 from EUR 56.60 at JPMorgan
TipRanks · 08/06 18:45
Fresenius SE price target raised to EUR 56 from EUR 55 at Deutsche Bank
TipRanks · 08/06 17:25
Deutsche Bank Sticks to Their Buy Rating for Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/06 11:45
Barclays Sticks to Their Buy Rating for Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/06 08:56
Fresenius SE Earnings Call Signals Confident Upswing
TipRanks · 08/06 00:20
J.P. Morgan Reaffirms Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/05 09:25
Jefferies Remains a Buy on Fresenius SE & Co. KGaA (0OO9)
TipRanks · 08/05 07:25
Fresenius announces FDA approval of rituximab biosimilar
TipRanks · 08/03 20:15
Weekly Report: what happened at FSNUY last week (0727-0731)?
Weekly Report · 08/03 10:21
Fresenius announces FDA, EMA acceptance of vedolizumab biosimilar for review
TipRanks · 07/31 11:11
Weekly Report: what happened at FSNUY last week (0720-0724)?
Weekly Report · 07/27 10:26
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Dow Jones · 07/22 10:34
Fresenius SE & Co. KGaA (0OO9) Gets a Buy from Jefferies
TipRanks · 07/21 22:11
More
Webull provides a variety of real-time FSNUY stock news. You can receive the latest news about Fresenius through multiple platforms. This information may help you make smarter investment decisions.
About FSNUY
Fresenius SE & Co. KGaA is a Germany-based healthcare group focused on products and services for the treatment of critically and chronically ill patients. The Company operates through its core businesses, Fresenius Kabi and Fresenius Helios. Fresenius Kabi develops and supplies biopharmaceuticals, clinical nutrition products, medical technologies, intravenously administered generic drugs, and infusion therapies. Fresenius Helios is Europe’s private healthcare provider, operating hospitals, outpatient centers, and other healthcare facilities in Germany, Spain, and Latin America. Fresenius also holds an investment in Fresenius Medical Care, a provider of dialysis products and services for patients with chronic kidney disease.